Cytokeratins (UBC and CYFRA 21-1) and molecular protein matrix as urinary tumor markers in the diagnosis of bladder cancer;Citoqueratinas (UBC y CYFRA 21-1) y proteínas de la matriz nuclear (NMP22) como marcadores tumorales en la orina en el diagnóstico del cáncer vesical

Medicina Clinica

Volumn 114, Issue 10, 2000, Pages 361-366

  Sánchez Carbayo, Marta ^a   Urrutia, Manuel ^a   Hernández Cerceño, María Luisa ^a   González De Buitrago, José Manuel ^a   Navajo, José Alejandro ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Bladder cancer; CYFRA 21 1; NMP22; UBC; Urine

Indexed keywords

ANTIGEN CYFRA21.1; BIOLOGICAL MARKER; CELL NUCLEUS ANTIGEN; KERATIN; NUCLEAR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; BIOLOGICAL MARKERS; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0034681674     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71298-X     Document Type: Article

References (31)

1. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1990; 13: 291-298.
2. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-1138.
3. Griffiths L, Neal DE. Prognostic markers in bladder cancer. Curr Opin Urol 1996; 6: 267-271.
4. Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996; 6; 272-279.
5. Foresman WH, Messing EM. Bladder cancer: natural history, tumor markers and early detection strategies. Semin Surg Oncol 1997; 13: 299-306.
6. Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol 1998; 16: 17-22.
7. Soloway MS. Do we have a prostate specific antigen for bladder cancer? J Urol 1999; 161; 447-448.
8. Sarosdy MF, DeVere White RW, Soloway MS, Shienfeld J, Hudson MA, Schellhammer PF et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379-384.
9. D'Hallewin MA, Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996; 155: 475-476.
10. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL et al. Use a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring trarsitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363-367.
11. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280-1285.
12. Stampfer DS, Carpinito GA, Rodríguez-Villanueva J, Willsey LW, Dinney CP, Grossman B et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394-398.
13. Landman J, Chang Y, Kavaler E. Droller MJ, Liu BC-S. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52: 398-402.
14. Schmetter BS, Habitch KK, Lamm DL, Morales A, Bander NH, Grossman HB et al. A multicenter trial evaluation of the fibrin/fribrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801-805.
15. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098-2101.
16. Fuchs E. Keratins as biochemical markers of epithelial differentiation. TIG 1988; 4: 277-284.
17. Moll R, Franke W, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-17.
18. Bodenmüller H. The biochemistry of CYFRA 21-1 and other cytokeratin-tests. Scand J Clin Lab Invest 1995; 221: 60-66.
19. Rydlander L, Ziegler E, Bergman T, Schöberl E, Steiner G, Bergman A-C et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-314.
20. Stieber P, Schmeller N, Schambeck CH, Hofmann K, Reiter W, Hasholzner U et al. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Anticancer Res 1996; 16: 3793-3798.
21. Silen A, Wiklund B, Andersson EL, Nilsson S. A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Scand J Clin Lab Invest 1995; 55: 153-161.
22. Sánchez-Carbayo M, Herrero E, Megías J, Mira A, Soria F. Initial evaluation of the new urinary bladder cancer antigen rapid test in the detection of transitional cell carcinoma of the bladder. Urology 1999; 54: 656-661.
23. Sánchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V et al. An initial evaluation of the diagnostic performance of the new urinary bladder antigen cancer test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999; 161: 1110-1115.
24. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Comm 1974; 60: 1410-1417.
25. Getzemberg RH. The nuclear matrix and the regulation of gene expression: tissue specificity. J Cell Biochem 1994; 55: 22-31.
26. Getzemberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56: 1690-1694.
27. Keesee S, Briggman JV, Thill G, Wu YJ. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Revin Eukaryiot Gene Expr 1996; 6: 189-214.
28. a ed.). Filadelfia: JB Lippincott Co., 1988; 194-195.
29. Mostofi FK. Histological typing of urinary gladder tumors. Ginebra; World Health Organization, 1973.
30. Sánchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megías J, Mira A et al. New electrochemiluminiscent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. En prensa.
31. Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997; 158: 338-341.